ArticleCureus2026
Lenvatinib-Associated Posterior Reversible Encephalopathy Syndrome in a Patient With Metastatic Clear Cell Renal Cell Carcinoma: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Posterior reversible encephalopathy syndrome (PRES) is a rare but serious neurologic complication associated with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors, including lenvatinib. We report a case of PRES in a 63-year-old woman with metastatic clear cell renal cell carcinoma treated with pembrolizumab and lenvatinib for isolated pancreatic metastases. Two days after lenvatinib initiation, she developed headaches, confusion, visual hallucinations, and a generalized tonic-clonic seizure in the setting of severe hypertension. Brain magnetic resonance imaging demonstrated bilateral parieto-occipital vasogenic edema consistent with PRES. Lenvatinib was discontinued, and she was treated with antihypertensive and antiepileptic therapy, with complete clinical recovery within two weeks with radiographic resolution on follow-up imaging. Pembrolizumab was maintained as monotherapy without PRES recurrence. This case highlights the importance of prompt recognition, drug discontinuation, blood pressure control, and supportive management in patients who develop neurologic symptoms shortly after starting VEGFR tyrosine kinase inhibitors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.